Amunix presents XTEN half-life extension technology at Next Generation Protein Therapeutics Summit
Amunix is presenting unpublished data on its XTEN half-life extension technology, which extends the half-life of biologically active molecules via chemical conjugation. The technology has been used to extend the half-life of genetically fused therapeutic proteins and peptides.